Soligenix (SNGX) Competitors $5.12 +2.34 (+84.06%) As of 03:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNGX vs. JSPR, OVID, STTK, ALXO, FGEN, PEPG, XLO, KPTI, ENLV, and SCYXShould you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Jasper Therapeutics (JSPR), Ovid Therapeutics (OVID), Shattuck Labs (STTK), ALX Oncology (ALXO), FibroGen (FGEN), PepGen (PEPG), Xilio Therapeutics (XLO), Karyopharm Therapeutics (KPTI), Enlivex Therapeutics (ENLV), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry. Soligenix vs. Its Competitors Jasper Therapeutics Ovid Therapeutics Shattuck Labs ALX Oncology FibroGen PepGen Xilio Therapeutics Karyopharm Therapeutics Enlivex Therapeutics SCYNEXIS Jasper Therapeutics (NASDAQ:JSPR) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends. Do analysts rate JSPR or SNGX? Jasper Therapeutics presently has a consensus target price of $28.75, suggesting a potential upside of 861.54%. Soligenix has a consensus target price of $6.00, suggesting a potential upside of 13.36%. Given Jasper Therapeutics' higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Soligenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Soligenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in JSPR or SNGX? 79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 4.6% of Jasper Therapeutics shares are held by company insiders. Comparatively, 3.1% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is JSPR or SNGX more profitable? Jasper Therapeutics' return on equity of -172.28% beat Soligenix's return on equity.Company Net Margins Return on Equity Return on Assets Jasper TherapeuticsN/A -172.28% -128.34% Soligenix N/A -233.65%-117.43% Which has more risk and volatility, JSPR or SNGX? Jasper Therapeutics has a beta of 2.7, suggesting that its stock price is 170% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Does the media refer more to JSPR or SNGX? In the previous week, Jasper Therapeutics had 5 more articles in the media than Soligenix. MarketBeat recorded 16 mentions for Jasper Therapeutics and 11 mentions for Soligenix. Jasper Therapeutics' average media sentiment score of -0.14 beat Soligenix's score of -0.19 indicating that Jasper Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Soligenix 1 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation and earnings, JSPR or SNGX? Soligenix has higher revenue and earnings than Jasper Therapeutics. Soligenix is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJasper TherapeuticsN/AN/A-$71.27M-$6.01-0.50Soligenix$120K143.79-$8.27M-$3.80-1.39 SummaryJasper Therapeutics beats Soligenix on 9 of the 14 factors compared between the two stocks. Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNGX vs. The Competition Export to ExcelMetricSoligenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.33M$3.13B$5.72B$9.77BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-1.4020.9330.9025.26Price / Sales143.79231.60403.8188.28Price / CashN/A41.5625.2228.45Price / Book3.239.749.516.00Net Income-$8.27M-$54.74M$3.26B$265.34M7 Day Performance116.93%7.94%4.48%2.84%1 Month Performance289.19%7.52%5.19%1.58%1 Year Performance39.29%17.41%31.75%25.40% Soligenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNGXSoligenix1.1579 of 5 stars$5.12+84.1%$6.00+17.3%-26.8%$16.58M$120K-1.3420News CoverageEarnings ReportAnalyst DowngradeGap UpHigh Trading VolumeJSPRJasper Therapeutics3.2631 of 5 stars$2.63+7.3%$29.75+1,031.2%-82.8%$36.80MN/A-0.5020News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpOVIDOvid Therapeutics4.4083 of 5 stars$0.56+7.9%$3.10+457.9%-14.2%$36.61M$570K-1.5960News CoverageEarnings ReportAnalyst UpgradeShort Interest ↑Analyst RevisionGap UpSTTKShattuck Labs3.5397 of 5 stars$0.74-2.3%$7.50+914.6%-70.2%$36.23M$5.72M-0.53100News CoverageEarnings ReportAnalyst RevisionALXOALX Oncology2.9025 of 5 stars$0.61-9.2%$3.30+437.0%-74.6%$36.14MN/A-0.2540Earnings ReportGap UpFGENFibroGen4.5856 of 5 stars$8.37-3.9%$43.00+413.7%+3.9%$35.20M$29.62M-3.35570News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionGap UpHigh Trading VolumePEPGPepGen3.2161 of 5 stars$1.01-5.6%$7.67+659.1%-86.3%$35.10MN/A-0.3430XLOXilio Therapeutics2.6121 of 5 stars$0.68+2.6%$3.00+341.0%-18.0%$34.33M$6.34M-0.8170Earnings ReportAnalyst DowngradeAnalyst RevisionHigh Trading VolumeKPTIKaryopharm Therapeutics3.8431 of 5 stars$3.77-4.3%$37.40+892.0%-51.8%$34.04M$145.24M-0.28380Earnings ReportGap DownENLVEnlivex Therapeutics3.3757 of 5 stars$1.47+2.8%$10.00+580.3%+44.4%$33.82MN/A-2.2370News CoverageAnalyst ForecastShort Interest ↓Gap DownTrading HaltedSCYXSCYNEXIS1.3825 of 5 stars$0.88+1.7%N/A-51.5%$33.75M$3.75M-1.5760Earnings ReportGap Down Related Companies and Tools Related Companies Jasper Therapeutics Competitors Ovid Therapeutics Competitors Shattuck Labs Competitors ALX Oncology Competitors FibroGen Competitors PepGen Competitors Xilio Therapeutics Competitors Karyopharm Therapeutics Competitors Enlivex Therapeutics Competitors SCYNEXIS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNGX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access